BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors European Society for Medical Oncology (ESMO 2024) to be held September 13-17, 2024 BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced abstracts for BI-1910 and BT-001 have been selected for presentation at ESMO 2024, being held in Barcelona, Spain from September 13th to 17th, 2024. BI-1910 is a monoclonal antibody, a TNFR2 agonist, currently enrolling patients in the monotherapy part of the ongoing Phase 1/2a study in patients with advanced solid tumors.
Why Goldman Sachs is helping its clients launch ETFs Firms should offer ETF products because investor demand is not slowing down, according to one Goldman Sachs ETF expert.
Hedge funds, family offices among those turning to Goldman Sachs ETF Accelerator Goldman Sachs Group's recently created business designed to help firms quickly launch exchange-traded funds has more than just traditional asset managers as clients.
Brandes Joins the Active Equity ETF Market With a more than 40-year heritage of value investing, Brandes made its debut in the ETF market today. The firm launched three actively managed equity ETFs, leveraging a partnership with Goldman Sachs ETF Accelerator.